BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25594072)

  • 1. A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells.
    Xu J; Agyemang S; Qin Y; Aysola K; Giles M; Oprea G; O'Regan RM; Partridge EE; Harris-Hooker S; Rice VM; Reddy ES; Rao VN
    Enliven Chall Cancer Detect Ther; 2014; 1(1):. PubMed ID: 25594072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.
    Qin Y; Xu J; Aysola K; Oprea G; Reddy A; Matthews R; Okoli J; Cantor A; Grizzle WE; Partridge EE; Reddy ES; Landen C; Rao VN
    Am J Cancer Res; 2012; 2(5):540-8. PubMed ID: 22957306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
    Desai A; Xu J; Aysola K; Akinbobuyi O; White M; Reddy VE; Okoli J; Clark C; Partridge EE; Childs E; Beech DJ; Rice MV; Reddy E; Rao VN
    J Gynecol Res; 2015; 1(1):. PubMed ID: 26665166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.
    Qin Y; Xu J; Aysola K; Begum N; Reddy V; Chai Y; Grizzle WE; Partridge EE; Reddy ES; Rao VN
    J Cell Physiol; 2011 Dec; 226(12):3355-67. PubMed ID: 21344391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
    Xu J; Footman A; Qin Y; Aysola K; Black S; Reddy V; Singh K; Grizzle W; You S; Moellering D; Reddy ES; Fu Y; Rao VN
    Int J Chronic Dis Ther; 2016; 2(3):31-38. PubMed ID: 28164176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel Ubc9 -dependent pathway regulates SIRT1- ER-α Axis and BRCA1-associated TNBC lung metastasis.
    Xu J; Shumate C; Qin Y; Reddy V; Burnam Y; Lopez V; Okoli J; P Reddy ES; Rao VN
    Integr Mol Med; 2017 Aug; 4(4):. PubMed ID: 31341634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
    Chai Y; Chipitsyna G; Cui J; Liao B; Liu S; Aysola K; Yezdani M; Reddy ES; Rao VN
    Oncogene; 2001 Mar; 20(11):1357-67. PubMed ID: 11313879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene.
    Wiechen K; Diatchenko L; Agoulnik A; Scharff KM; Schober H; Arlt K; Zhumabayeva B; Siebert PD; Dietel M; Schäfer R; Sers C
    Am J Pathol; 2001 Nov; 159(5):1635-43. PubMed ID: 11696424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
    Wang H; Shao N; Ding QM; Cui J; Reddy ES; Rao VN
    Oncogene; 1997 Jul; 15(2):143-57. PubMed ID: 9244350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers.
    Yuli C; Shao N; Rao R; Aysola P; Reddy V; Oprea-llies G; Lee L; Okoli J; Partridge E; Reddy ES; Rao VN
    Oncogene; 2007 Sep; 26(41):6031-7. PubMed ID: 17384678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
    Weberpals JI; Clark-Knowles KV; Vanderhyden BC
    J Clin Oncol; 2008 Jul; 26(19):3259-67. PubMed ID: 18591560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
    Cui JQ; Wang H; Reddy ES; Rao VN
    Oncol Rep; 1998; 5(3):585-9. PubMed ID: 9538156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
    Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
    Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
    Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
    J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.